USE OF FDA-APPROVED ALZHEIMER'S DISEASE MEDICATIONS AMONG NON-INSTITUTIONALIZED U.S. ADULTS AGE 60 YEARS AND OLDER
Steven Frenk, 1 and Jessica M. Sautter 2 , 1. CDC/National Center for Health Statistics, Hyattsville, Maryland, United States, 2. University of the Sciences, Philadelphia, Pennsylvania, United States This study examined the use of Alzheimer's Disease medications (ADMs) among non-institutionalized U.S. adults aged 60 years and older. It described the characteristics of ADM users, compared them to adults who were not currently using ADMs, and examined how demographic characteristics, living arrangements, healthcare utilization, and self-perceived cognition are associated with use of ADMs. It also identified the duration of ADM use and the most commonly used ADMs. Data come from the National Health and Nutrition Examination Survey, a nationally representative study of the non-institutionalized U.S. population (2009) (2010) (2011) (2012) (2013) (2014) . Respondents were classified as ADM users if they reported using one or more of the following prescription ADMs in the past 30 days: donepezil, rivastigmine, memantine, galantamine, or a drug combination of donepezil and memantine. During the study period, 1.9% of non-institutionalized U.S. adults aged 60 years and older reported using an ADM in the past 30 days. Use of ADMs was associated with concurrent use of antidepressant medications and also frequent or worsening memory loss and confusion. Most ADM users (82.3%) reported using ADMs for more than one year and the most frequently used ADM was donepezil. In 2009-2014, about 1.1 million non-institutionalized adults aged 60 years and older used an ADM in the past 30 days. They reported relatively poor cognitive abilities, frequent healthcare utilization, and concurrent use of antidepressant medications compared to non-users. Newly released public survey data will be useful to provide updated estimates of ADM use in the community. Assistive technology has been recognized as a promising tool to improve the lives of persons living with dementia and their caregivers. The use of assistive technology in dementia care is expanding, although it is most often applied to manage care and promote safety. There is a lack of assistive technology designed to aid persons with dementia to participate in meaningful activities. The present study utilizes a pilot randomized controlled trial (RCT) design to evaluate the feasibility, acceptability, and effects of an assistive technology device, the Social Support Aid (SSA), designed to assist persons with dementia engage in social interaction. Quantitative data were collected initially and three and six months later, and participants in the technology group participated in qualitative interviews. Feasibility and utility scores indicated that participants felt neutral about the technology. Use of the SSA was not significantly associated with changes in quality of social interactions or quality of life measures over the six months of follow-up (P > .05). The qualitative analysis revealed three themes that described how and why the SSA worked or did not: (1) outcomes (2) reasons why (not) useful and (3) recommendations. There is a need to develop effective assistive technology that improves the quality of life of persons with dementia. Assistive technology that allows persons living with dementia to maintain some level of autonomy should be a priority for future research. Results provide recommendations for future assistive technology development and evaluation. Innovation in Aging, 2019, Vol. 3, No. S1 
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